OTCMKTS:HCYTD H-CYTE - HCYTD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.02 -1.98 (-49.50%) (As of 07/11/2022) Add Compare Share Share Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About H-CYTE (OTCMKTS:HCYTD) StockH-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address HCYTD Stock News HeadlinesSeptember 8, 2022 | finance.yahoo.comH-CYTE Completes Acquisition of JantibodyJuly 23, 2022 | apnews.comH-CYTE to Expect the Completed Acquisition of Jantibody Within 30 DaysFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...June 13, 2022 | finance.yahoo.comH-CYTE Announces 1-for-1,000 Reverse Stock SplitMarch 4, 2022 | finance.yahoo.comH-CYTE Announces Proceeds of $1.05 Million from Warrant ExerciseFebruary 7, 2022 | nasdaq.comH-CYTE Inc (HCYT)January 11, 2022 | seekingalpha.comH-CYTE signs letter of intent to acquire Catheter PrecisionJanuary 11, 2022 | finance.yahoo.comH-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.February 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 6, 2021 | finance.yahoo.comH-CYTE Names Michael Yurkowsky Chief Executive OfficerSeptember 9, 2021 | au.finance.yahoo.comItalian court seeks opinion on Berlusconi's health due to trial delaysSeptember 8, 2021 | finance.yahoo.comH-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory HealthJuly 7, 2021 | ca.finance.yahoo.comJefferson Lines takes proactive steps toward crisis management with TSA I-STEP trainingJuly 7, 2021 | in.finance.yahoo.comScanfil plc: Managers' transactions – JokitaloJuly 6, 2021 | finance.yahoo.comH-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung HealthJuly 1, 2021 | in.finance.yahoo.comConstellium supplies advanced aluminium solutions for the electric Audi e-tron GTJuly 1, 2021 | au.finance.yahoo.comNetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon MagazineJune 29, 2021 | finance.yahoo.comH-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung HealthOctober 4, 2020 | msn.comNew Providence CEO: 'We have a responsibility and accountability to the community'September 29, 2020 | feeds.benzinga.comRobert Greif named Chief Executive Officer of H-CYTESeptember 27, 2020 | marketwatch.comThree Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QROSeptember 2, 2020 | finance.yahoo.comH-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020July 6, 2020 | www.nasdaq.comTSX rises on energy gains, U.S. services sector reboundJuly 6, 2020 | www.reuters.comCANADA STOCKS-TSX rises on energy gains, U.S. services sector reboundApril 21, 2020 | finance.yahoo.comPrairie Provident Provides an Update on Lending FacilityMarch 26, 2020 | www.globenewswire.comPrairie Provident Resources Announces Fourth Quarter and Year-End 2019 Financial and Operating ResultsFebruary 18, 2020 | www.globenewswire.comPrairie Provident Resources Announces Updated Corporate PresentationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address HCYTD Company Calendar Today2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & Medical Instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HCYTD CUSIPN/A CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 Key ExecutivesMr. Michael W. Yurkowsky (Age 50)CEO & Director Comp: $180kMr. Jeremy Daniel (Age 46)Chief Financial Officer Comp: $200kDr. Tanya Rhodes Ph.D. (Age 61)Chief Scientific Officer Comp: $252kMr. Jeffery Wright CPA (Age 39)CPA, Controller & Principal Accounting Officer Key CompetitorsHypertension DiagnosticsOTCMKTS:HDIIQuantRx BiomedicalOTCMKTS:QTXBPresbiaOTCMKTS:LENSFVerisante TechnologyOTCMKTS:VRSEFSafeplus InternationalOTCMKTS:ACAIView All Competitors HCYTD Stock - Frequently Asked Questions How have HCYTD shares performed in 2023? H-CYTE's stock was trading at $2.02 at the beginning of 2023. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2023 here. What is H-CYTE's stock symbol? H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD." How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is H-CYTE's stock price today? One share of HCYTD stock can currently be purchased for approximately $2.02. How much money does H-CYTE make? H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year. How can I contact H-CYTE? H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com. This page (OTCMKTS:HCYTD) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.